Vascular Biogenics Ltd. Income Statement 2023-2011 | VBLT

Brief overview of income trends at Vascular Biogenics Ltd.

This overview is based on financial performance over the past five years. Revenue reported by Vascular Biogenics Ltd. was $585 thousand at the beginning of the period and $310 thousand at the end. The total change was −47%, with a CAGR of approximately −11.9%. The business finished the period with a smaller revenue base.

The five-year change in gross profit reached −65.8%: from 330 thousand dollars to 113 thousand dollars. Cost of revenue developed less favorably than sales and pressured gross profitability. At the margin level, the figure shifted from 56.4% to 36.5%. Weakening gross profitability reduces the quality of the top-line trend.

The operating result measured by EBITDA moved from $22.4 million to −$14.4 million, or −164.3%. Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of 3829.2% and −4645.2%. A lower EBITDA share weakens the quality of the result.

Across the five years, the net result shifted from $20.5 million to −$11.3 million. Profit turned into a loss, the most concerning signal in the results.

Financial takeaway

The current trajectory does not yet confirm a sustainable recovery. The weaker side of the profile includes a narrow EBITDA buffer, pressure from direct costs and weak sales momentum. Further direction will depend on top-line growth, operating profitability, and net income.